Non-functioning Pituitary AdenomaNCT07763236
Indocyanine Green Fluorescence in Endoscopic Resection of Non-Functioning Pituitary Adenomas
A study testing Endoscopic endonasal transsphenoidal surgery and Indocyanine Green dye in people with Non-functioning Pituitary Adenoma, run by Tomislav Felbabić at 1 site in Slovenia.
Trial summary
The goal of this study was to determine whether ICG improves outcomes in surgery for non-functioning macroadenomas. The main questions it aimed to answer were: Was gross total resection more frequent? Did ICG use lead to fewer intraoperative and postoperative complications? The investigators compared the ICG group… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-functioning Pituitary Adenoma
- What is being tested?
- Endoscopic endonasal transsphenoidal surgery and Indocyanine Green dye
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 siteSlovenia
- Study dates
- 19 Feb 2019to 25 Mar 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Presence of non-functioning pituitary macroadenoma, which needs surgical removal
- Agrees to participate
Who cannot join
- Age under 18 years
- Iodine allergy
- Pregnancy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Intraoperative Fluorescence and Surgical Outcomes in Endoscopic Resection of Non-functioning Pituitary Macroadenomas: A Pilot Randomised Study
The goal of this study was to determine whether ICG improves outcomes in surgery for non-functioning macroadenomas. The main questions it aimed to answer were:
Was gross total resection more frequent? Did ICG use lead to fewer intraoperative and postoperative complications?
The investigators compared the ICG group with the control group to determine whether there were differences in outcomes between the groups.
Participants received ICG intraoperatively if they had been randomly assigned to the ICG group.
Read the detailed description
It is important to distinguish between the tumour and healthy tissue. This allows for maximum tumour removal with minimal damage to surrounding structures. In neurosurgery, various dyes are already used for specific medical conditions and have been shown to improve treatment outcomes. One example is 5-aminolevulinic acid (5-ALA), which is most commonly used in surgeries for primary brain tumours but also shows potential benefit in surgeries for meningiomas and brain metastases. Sodium fluorescein (SF) offers similar benefits in these pathologies. Both dyes accumulate in tumour tissues due to a compromised blood-brain barrier (BBB). The use of both dyes has been investigated in endoscopic endonasal surgeries. 5-ALA does not yet show significant benefit in these surgeries. SF has shown some potential benefits, but so far the literature is sparse. It is suggested that there is a quantitative difference in the degree of fluorescence of tumour tissue compared to surrounding structures, but these differences cannot be subjectively determined intraoperatively. On the other hand, ICG has proven to be a promising intraoperative marker. After intravenous administration, the dye causes the veins to fluoresce, including the capillaries. Because ICG can highlight capillary flow, it has increasing potential in endoscopic pituitary surgery. As adenomas have significantly lower capillary density compared to normal pituitary tissue, they do not fluoresce after ICG administration, whereas the pituitary gland does.
To date, no randomised, prospective studies have been published, which compare surgical complications in patients operated on with the conventional method and those operated on with ICG. In our exploratory study, the investigators aimed to determine the feasibility of intraoperative use of ICG dye and whether it would result in fewer complications and more frequent complete removal of the adenoma. If feasibility is confirmed, this could demonstrate the potential added value of ICG in endoscopic endonasal surgery of pituitary adenomas, resulting in better patient outcomes.
A prospective, randomised, pilot clinical study, single-blinded for patients and for radiological and ophthalmological outcome assessment, was conducted in the Clinical Department of Neurosurgery at the University Medical Centre Ljubljana, Slovenia. The study was approved by the Medical Ethics Committee of the Republic of Slovenia (No. 0120-56/2019/6). It was not registered with the clinical trial registry prospectively, because it was considered small, pilot, single-centre investigation and was not required by the institution where the study was taking place at the time it was initiated. The investigators included all non-functional pituitary macroadenoma patients surgically treated at the hospital during the period between February 2019 and March 2023, who were not allergic to iodine, were older than 18 years, were not pregnant, and consented to participate. Patients were randomly divided into two groups: one group received ICG during surgery, while the other served as the control group. Randomisation was performed using block randomisation in a 1:1 ratio. Blocks of sizes 4 and 6 were used, with participants randomly assigned within each block to ensure a balanced number of participants in both groups. The randomisation sequence was generated by an independent researcher. Given the exploratory nature of the study and limited patient availability at our centre, the sample size was not based on an a priori power calculation. Instead, it was determined by the number of eligible patients who could be recruited within the available time frame.
Surgical technique In all patients, an endoscopic endonasal transsphenoidal approach was used to remove the pituitary macroadenoma, which the investigators extended with a transplanar, transtubercular (intensive suprasellar tumour extension) or transpterigoid (parasellar extension into the lateral compartment) approach if necessary. In all cases, the investigators operated only through the left nostril, lateralised the middle turbinate, performed a posterior septotomy and a sphenoidotomy. For extended approaches, where there was an intraoperative cerebrospinal fluid (CSF) leak, the investigators made a nasoseptal (Hadad) flap. The posterior sphenoidotomy extended from one anterior loop of the intracavernous carotid artery to the other; in cases of extension into the cavernous sinus, the investigators extended the access on the ipsilateral side with a posterior ethmoidotomy, drilling of the lateral wall of the sphenoid sinus, and a modified transpterigoid approach.
The investigators have opened the dura of the sella turcica with a circular incision. These steps allowed maximal exposure of the macroadenoma, which could then be removed. The investigators did not use curettage as there were no blind spots in the field of view; every part of the surgical field could be seen with the camera. After exposing the intrasellar space, the investigators first administered ICG dye intravenously to improve differentiation between the pituitary gland and the tumour. The carotid artery was stained after about 15-20 seconds, the pituitary gland after 20-30 seconds. After complete macroscopic removal of the tumour, the investigators administered ICG a second time to check the surgical field for any remaining tumour residue. The investigators used a technique of stepwise tumour removal with systematic keyhole aspiration along the border between the adenoma and the pituitary gland. First, the investigators removed part of the tumour at the base of the sella turcica, then along the medial walls of the cavernous sinuses, while the suprasellar part gradually folded downwards. After complete removal, closure was performed using an artificial dural substitute (DuraGen Secure, Integra LifeSciences, Princeton, NJ, USA) as an onlay graft, which was additionally reinforced with TachoSil patches (Takeda Pharmaceuticals, Tokyo, Japan). The diaphragma sellae was further supported with Spongostan (Ethicon, Somerville, NJ, USA), and the reconstruction was sealed with DuraSeal fibrin sealant (Integra LifeSciences, Princeton, NJ, USA). In the three cases where a Hadad flap was used, the flap was first positioned and then reinforced with TachoSil, Spongostan, and DuraSeal sealant. At the end of the procedure, Rapid Rhino nasal tampons (Smith \& Nephew, Watford, UK) were inserted into both nostrils and removed 1-2 days postoperatively.
Indocyanine green dye The investigators used the ICG dye (Serb, Paris, France). 25 mg of the ICG dye was dissolved in 10 mL of sterile water. After exposing the intrasellar space, the investigators injected 5 mL of the solution (12.5 mg ICG) intravenously as a bolus during surgery and after macroscopic removal of the macroadenoma.
Optics For endoscopic endonasal transsphenoidal surgery, the investigators used a rigid endoscope Karl Storz 7230AA Hopkins II Telescope 0°, 4 mm/18 cm, Tuttlingen, Germany. For this study, an endoscope with ICG light detection, Karl Storz 8710AGA Hopkins II Rigid ENT Scope 0°, 5.8 mm/20 cm, was used in the ICG group. During the operation, the light source could be switched between white and near-infrared light using a switch on the foot pedal.
Radiological evaluation All patients underwent MR imaging of the head with contrast medium before and 3 to 6 months after surgery according to pituitary gland protocol. Tumour dimensions were measured in the transverse, sagittal and coronal planes. Tumour volume was calculated as half the product of all three dimensions. Tumours were classified according to Knosp based on coronal sequences and Hardy based on sagittal sequences. The parasellar extension was additionally assessed according to Miranda's classification, which describes into which compartment of the cavernous sinus the tumour had invaded.
Assessment of complications Intraoperative complications such as cerebrospinal fluid (CSF) leak, damage to the carotid artery and cavernous nerves were assessed during surgery. For postoperative complications, the investigators paid attention to postoperative CSF leak, tumour residue, visual disturbances, postoperative haematoma, meningitis, double vision and facial dysaesthesia. CSF leak was confirmed by increased beta trace levels in nasal discharge or by direct endoscopic examination of the surgical site by otolaryngologist. Tumour remnants were assessed by MRI examination according to pituitary gland protocol 3-6 months after surgery by radiologist, blinded to the treatment modality. Any radiological finding suggestive of residual tumour, including ambiguous finding, was classified as a residual. All patients underwent a visual field examination before and 3-6 months after surgery by an ophthalmologist, who was also blinded to the treatment modality. Haematoma was confirmed by CT scan of the head. Meningitis was determined by microbiological isolation of bacteria from CSF samples, while double vision and facial dysaesthesia were determined based on the patient's clinical presentation.
Statistical analysis of data The data were analysed using the statistical programme SPSS 25 (IBM Corp., Armonk, USA). P values of less than 0.05 were considered statistically significant.
Demographic and clinical characteristics of patients that were normally distributed were presented as arithmetic mean and standard deviation, while asymmetrically distributed variables were presented as median and first and third quartiles. 95% confidence intervals were derived from sample standard deviation. Categorical variables were presented as relative and absolute frequencies.
To compare the proportions between the groups of patients with and without ICG dye, the investigators used the chi-square test or Fisher's exact test.
- Conditions
- Non-functioning Pituitary Adenoma
- Being tested
- Endoscopic endonasal transsphenoidal surgery, Indocyanine Green dye
- Keywords
- pituitary, non-functioning macroadenomas, endoscopic endonasal surgery, pilot study, indocyanine green
- Medical subject headings
- Pituitary Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endoscopic endonasal transsphenoidal surgeryProcedure or surgery
Endoscopic endonasal transsphenoidal resection of non-functioning pituitary macroadenomas.
Indocyanine Green dyeDrug
Intravenous administration of indocyanine green during surgery to provide intraoperative fluorescence visualization during endoscopic resection of non-functioning pituitary macroadenomas.
| Study group | Role | What they receive |
|---|---|---|
| ICG fluorescence group | Experimental | Participants underwent endoscopic endonasal transsphenoidal resection of non-functioning pituitary macroadenomas with intraoperative indocyanine green fluorescence visualization. Receives: Procedure: Endoscopic endonasal transsphenoidal surgery; Drug: Indocyanine Green dye |
| Control group | Active comparator | Participants underwent standard endoscopic endonasal transsphenoidal resection of non-functioning pituitary macroadenomas without intraoperative indocyanine green fluorescence visualization. Receives: Procedure: Endoscopic endonasal transsphenoidal surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Complete tumor resection
Proportion of participants with no residual tumor identified on contrast-enhanced magnetic resonance imaging (MRI) performed 3-6 months after surgery. MRI examinations were assessed by neuroradiologists who were blinded to treatment allocation.
Measured: 3-6 months after surgery
Secondary outcomes (4)
Postoperative visual outcome
Change in visual function following surgery, assessed by postoperative ophthalmological examination and compared with the preoperative examination. Visual outcome was categorized as improved, unchanged, or deteriorated and expressed as the percentage of participants in each category (%). Visual function was assessed using visual acuity and visual field examinations by an ophthalmologist blinded to treatment allocation.
Measured: 3-6 months after surgery
Intraoperative cerebrospinal fluid leak
Percentage of participants with intraoperative cerebrospinal fluid (CSF) leak, assessed by direct intraoperative observation during surgery and documented in the operative report.
Measured: During surgery
Postoperative cerebrospinal fluid leak
Percentage of participants with postoperative cerebrospinal fluid (CSF) leak, assessed by detection of beta-trace protein in nasal discharge and/or direct endoscopic examination of the nasal cavity.
Measured: Within 14 days after surgery
Other postoperative complications
Incidence of other postoperative surgery-related complications, including postoperative hematoma, meningitis, and cranial nerve palsy. Hematoma was assessed by cranial CT image, meningitis was determined by microbiological isolation of bacteria from CSF samples, cranial nerve palsy was determined by postoperative clinical examination.
Measured: Within 14 days after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2026
- Study start19 Feb 2019
- Primary completion19 Oct 2022
- Study completion25 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-functioning Pituitary AdenomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tomislav Felbabić
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Tomislav Felbabić, University Medical Centre Ljubljana
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07763236
- Sponsor's protocol ID
- UKCLJ-NEURO-ICG-001
- Status last verified
- Aug 2026
- First submitted
- 4 Aug 2026
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be made available because of ethical and data protection considerations. Due to the single-center design and small sample size, sharing individual-level data may pose a risk of participant identification.
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intraoperative Fluorescence and Surgical Outcomes in Endoscopic Resection of Non-functioning Pituitary Macroadenomas: A Pilot Randomised Study
- ClinicalTrials.gov ID
- NCT07763236
- Acronym / sponsor ID
- UKCLJ-NEURO-ICG-001
- Conditions
- Non-functioning Pituitary Adenoma
- Keywords
- pituitary, non-functioning macroadenomas, endoscopic endonasal surgery, pilot study, indocyanine green
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Tomislav FelbabićUniversity, hospital or other
- Study start
- 19 Feb 2019 (actual)
- Primary completion
- 19 Oct 2022 (actual)
- Study completion
- 25 Mar 2023 (actual)
- First posted
- 13 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study was to determine whether ICG improves outcomes in surgery for non-functioning macroadenomas. The main questions it aimed to answer were:
Was gross total resection more frequent? Did ICG use lead to fewer intraoperative and postoperative complications?
The investigators compared the ICG group with the control group to determine whether there were differences in outcomes between the groups.
Participants received ICG intraoperatively if they had been randomly assigned to the ICG group.
Detailed description
It is important to distinguish between the tumour and healthy tissue. This allows for maximum tumour removal with minimal damage to surrounding structures. In neurosurgery, various dyes are already used for specific medical conditions and have been shown to improve treatment outcomes. One example is 5-aminolevulinic acid (5-ALA), which is most commonly used in surgeries for primary brain tumours but also shows potential benefit in surgeries for meningiomas and brain metastases. Sodium fluorescein (SF) offers similar benefits in these pathologies. Both dyes accumulate in tumour tissues due to a compromised blood-brain barrier (BBB). The use of both dyes has been investigated in endoscopic endonasal surgeries. 5-ALA does not yet show significant benefit in these surgeries. SF has shown some potential benefits, but so far the literature is sparse. It is suggested that there is a quantitative difference in the degree of fluorescence of tumour tissue compared to surrounding structures, but these differences cannot be subjectively determined intraoperatively. On the other hand, ICG has proven to be a promising intraoperative marker. After intravenous administration, the dye causes the veins to fluoresce, including the capillaries. Because ICG can highlight capillary flow, it has increasing potential in endoscopic pituitary surgery. As adenomas have significantly lower capillary density compared to normal pituitary tissue, they do not fluoresce after ICG administration, whereas the pituitary gland does.
To date, no randomised, prospective studies have been published, which compare surgical complications in patients operated on with the conventional method and those operated on with ICG. In our exploratory study, the investigators aimed to determine the feasibility of intraoperative use of ICG dye and whether it would result in fewer complications and more frequent complete removal of the adenoma. If feasibility is confirmed, this could demonstrate the potential added value of ICG in endoscopic endonasal surgery of pituitary adenomas, resulting in better patient outcomes.
A prospective, randomised, pilot clinical study, single-blinded for patients and for radiological and ophthalmological outcome assessment, was conducted in the Clinical Department of Neurosurgery at the University Medical Centre Ljubljana, Slovenia. The study was approved by the Medical Ethics Committee of the Republic of Slovenia (No. 0120-56/2019/6). It was not registered with the clinical trial registry prospectively, because it was considered small, pilot, single-centre investigation and was not required by the institution where the study was taking place at the time it was initiated. The investigators included all non-functional pituitary macroadenoma patients surgically treated at the hospital during the period between February 2019 and March 2023, who were not allergic to iodine, were older than 18 years, were not pregnant, and consented to participate. Patients were randomly divided into two groups: one group received ICG during surgery, while the other served as the control group. Randomisation was performed using block randomisation in a 1:1 ratio. Blocks of sizes 4 and 6 were used, with participants randomly assigned within each block to ensure a balanced number of participants in both groups. The randomisation sequence was generated by an independent researcher. Given the exploratory nature of the study and limited patient availability at our centre, the sample size was not based on an a priori power calculation. Instead, it was determined by the number of eligible patients who could be recruited within the available time frame.
Surgical technique In all patients, an endoscopic endonasal transsphenoidal approach was used to remove the pituitary macroadenoma, which the investigators extended with a transplanar, transtubercular (intensive suprasellar tumour extension) or transpterigoid (parasellar extension into the lateral compartment) approach if necessary. In all cases, the investigators operated only through the left nostril, lateralised the middle turbinate, performed a posterior septotomy and a sphenoidotomy. For extended approaches, where there was an intraoperative cerebrospinal fluid (CSF) leak, the investigators made a nasoseptal (Hadad) flap. The posterior sphenoidotomy extended from one anterior loop of the intracavernous carotid artery to the other; in cases of extension into the cavernous sinus, the investigators extended the access on the ipsilateral side with a posterior ethmoidotomy, drilling of the lateral wall of the sphenoid sinus, and a modified transpterigoid approach.
The investigators have opened the dura of the sella turcica with a circular incision. These steps allowed maximal exposure of the macroadenoma, which could then be removed. The investigators did not use curettage as there were no blind spots in the field of view; every part of the surgical field could be seen with the camera. After exposing the intrasellar space, the investigators first administered ICG dye intravenously to improve differentiation between the pituitary gland and the tumour. The carotid artery was stained after about 15-20 seconds, the pituitary gland after 20-30 seconds. After complete macroscopic removal of the tumour, the investigators administered ICG a second time to check the surgical field for any remaining tumour residue. The investigators used a technique of stepwise tumour removal with systematic keyhole aspiration along the border between the adenoma and the pituitary gland. First, the investigators removed part of the tumour at the base of the sella turcica, then along the medial walls of the cavernous sinuses, while the suprasellar part gradually folded downwards. After complete removal, closure was performed using an artificial dural substitute (DuraGen Secure, Integra LifeSciences, Princeton, NJ, USA) as an onlay graft, which was additionally reinforced with TachoSil patches (Takeda Pharmaceuticals, Tokyo, Japan). The diaphragma sellae was further supported with Spongostan (Ethicon, Somerville, NJ, USA), and the reconstruction was sealed with DuraSeal fibrin sealant (Integra LifeSciences, Princeton, NJ, USA). In the three cases where a Hadad flap was used, the flap was first positioned and then reinforced with TachoSil, Spongostan, and DuraSeal sealant. At the end of the procedure, Rapid Rhino nasal tampons (Smith \& Nephew, Watford, UK) were inserted into both nostrils and removed 1-2 days postoperatively.
Indocyanine green dye The investigators used the ICG dye (Serb, Paris, France). 25 mg of the ICG dye was dissolved in 10 mL of sterile water. After exposing the intrasellar space, the investigators injected 5 mL of the solution (12.5 mg ICG) intravenously as a bolus during surgery and after macroscopic removal of the macroadenoma.
Optics For endoscopic endonasal transsphenoidal surgery, the investigators used a rigid endoscope Karl Storz 7230AA Hopkins II Telescope 0°, 4 mm/18 cm, Tuttlingen, Germany. For this study, an endoscope with ICG light detection, Karl Storz 8710AGA Hopkins II Rigid ENT Scope 0°, 5.8 mm/20 cm, was used in the ICG group. During the operation, the light source could be switched between white and near-infrared light using a switch on the foot pedal.
Radiological evaluation All patients underwent MR imaging of the head with contrast medium before and 3 to 6 months after surgery according to pituitary gland protocol. Tumour dimensions were measured in the transverse, sagittal and coronal planes. Tumour volume was calculated as half the product of all three dimensions. Tumours were classified according to Knosp based on coronal sequences and Hardy based on sagittal sequences. The parasellar extension was additionally assessed according to Miranda's classification, which describes into which compartment of the cavernous sinus the tumour had invaded.
Assessment of complications Intraoperative complications such as cerebrospinal fluid (CSF) leak, damage to the carotid artery and cavernous nerves were assessed during surgery. For postoperative complications, the investigators paid attention to postoperative CSF leak, tumour residue, visual disturbances, postoperative haematoma, meningitis, double vision and facial dysaesthesia. CSF leak was confirmed by increased beta trace levels in nasal discharge or by direct endoscopic examination of the surgical site by otolaryngologist. Tumour remnants were assessed by MRI examination according to pituitary gland protocol 3-6 months after surgery by radiologist, blinded to the treatment modality. Any radiological finding suggestive of residual tumour, including ambiguous finding, was classified as a residual. All patients underwent a visual field examination before and 3-6 months after surgery by an ophthalmologist, who was also blinded to the treatment modality. Haematoma was confirmed by CT scan of the head. Meningitis was determined by microbiological isolation of bacteria from CSF samples, while double vision and facial dysaesthesia were determined based on the patient's clinical presentation.
Statistical analysis of data The data were analysed using the statistical programme SPSS 25 (IBM Corp., Armonk, USA). P values of less than 0.05 were considered statistically significant.
Demographic and clinical characteristics of patients that were normally distributed were presented as arithmetic mean and standard deviation, while asymmetrically distributed variables were presented as median and first and third quartiles. 95% confidence intervals were derived from sample standard deviation. Categorical variables were presented as relative and absolute frequencies.
To compare the proportions between the groups of patients with and without ICG dye, the investigators used the chi-square test or Fisher's exact test.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ICG fluorescence group | Experimental | Procedure: Endoscopic endonasal transsphenoidal surgery, Drug: Indocyanine Green dyeParticipants underwent endoscopic endonasal transsphenoidal resection of non-functioning pituitary macroadenomas with intraoperative indocyanine green fluorescence visualization. |
| Control group | Active comparator | Procedure: Endoscopic endonasal transsphenoidal surgeryParticipants underwent standard endoscopic endonasal transsphenoidal resection of non-functioning pituitary macroadenomas without intraoperative indocyanine green fluorescence visualization. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Presence of non-functioning pituitary macroadenoma, which needs surgical removal
- Agrees to participate
Key exclusion criteria (3 listed)
- Age under 18 years
- Iodine allergy
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endoscopic endonasal transsphenoidal surgeryEndoscopic endonasal transsphenoidal resection of non-functioning pituitary macroadenomas. | Procedure or surgery | Control group, ICG fluorescence group |
| Indocyanine Green dyeIntravenous administration of indocyanine green during surgery to provide intraoperative fluorescence visualization during endoscopic resection of non-functioning pituitary macroadenomas. | Drug | ICG fluorescence group |
Primary outcome
Complete tumor resection
Time frame: 3-6 months after surgery
Proportion of participants with no residual tumor identified on contrast-enhanced magnetic resonance imaging (MRI) performed 3-6 months after surgery. MRI examinations were assessed by neuroradiologists who were blinded to treatment allocation.
4 secondary outcomes
Postoperative visual outcome
Time frame: 3-6 months after surgery
Intraoperative cerebrospinal fluid leak
Time frame: During surgery
Postoperative cerebrospinal fluid leak
Time frame: Within 14 days after surgery
Other postoperative complications
Time frame: Within 14 days after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be made available because of ethical and data protection considerations. Due to the single-center design and small sample size, sharing individual-level data may pose a risk of participant identification.
Related trials for Non-functioning Pituitary Adenoma
Active, not recruitingPhase 3
Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas
Pituitary Neoplasms, Adenoma
Not yet recruitingObservational study
Direct Versus Video Laryngoscopy in Patients With Acromegaly
Acromegaly, Nonfunctioning Pituitary Adenoma
Enrolling by invitation
Physical Attendance Versus Telephone or Video Follow-up in Patients With Non-functioning Pituitary Tumors.
Non-Functional Pituitary Adenoma
Recruiting
Individualized Physical Activity or Patients With Non Functioning Pituitary Adenoma
Non-functioning Pituitary Adenoma
Enrolling by invitationPhase 4
Cabergoline in the Management of Nonfunctioning Pituitary Adenoma
Pituitary Adenoma, MRI
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Endoscopic endonasal transsphenoidal surgery and Indocyanine Green dye in people with Non-functioning Pituitary Adenoma, run by Tomislav Felbabić at 1 site in Slovenia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complete tumor resection (time frame: 3-6 months after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.